Zanolimumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) m →References: Resolve template redirect, replaced: {{humanmonoclonals}} → {{Monoclonals for immune system}} using AWB |
Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:Wi |
||
Line 1: | Line 1: | ||
{{drugbox |
{{drugbox |
||
| verifiedrevid = 380052280 |
|||
| type = mab |
| type = mab |
||
| image = |
| image = |
Revision as of 08:20, 19 December 2010
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
Chemical and physical data | |
Molar mass | 147 kDa |
(verify) |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma [2], cutaneous and peripheral T-cell lymphoma.[3][4]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ http://www.tenxbiopharma.com/development.shtml
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov